Omnicell Inc. (OMCL)
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks is more attractive to value investors?
Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Omnicell: Why I'm Long Into Q2 Earnings Despite The Bookings Wobble
Omnicell is rated Buy, with Q1 results showing structural margin improvement and a 660 bps operating margin jump. Q1 revenue grew 15% Y/Y to $310M, with non-GAAP EPS of $0.55 beating guidance by 53% and free cash flow tripling to $39M. Management raised FY 2026 EBITDA guidance, expects margin expansion to outpace revenue growth, and continues share repurchases.
Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 40.6% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Omnicell (OMCL) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Omnicell Stock a Smart Addition to Your Portfolio Now?
OMCL rides on SaaS growth, Autonomous Pharmacy adoption and expansion plans, but rising costs and competition could test its momentum.
Omnicell (OMCL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Omnicell (OMCL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Omnicell (OMCL) Up 0.1% Since Last Earnings Report: Can It Continue?
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?
Omnicell Stock Surges 57.3% in a Year: What's Driving It?
OMCL shares soar 57.3% in a year as SaaS growth, Autonomous Pharmacy momentum and OmniSphere adoption boost outlook.
Should You Buy Omnicell (OMCL) After Golden Cross?
Omnicell, Inc. (OMCL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, OMCL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
How Much Upside is Left in Omnicell (OMCL)? Wall Street Analysts Think 39.87%
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
